Table 2.

Studies investigating the use of SBRT in oligometastatic breast and colorectal cancer

Study	Patients	Eligibility criteria	Study design	Site of metastases	Therapy	Median follow-up (months)	Median PFS (months)	Median OS (months)	Other therapy (percentage)
Breast cancer
Milano et al. [35]	40	<5 extracranial metastases	subgroup analysis of a prospective Phase II trial	liver, lung, lymph nodes, bone	SBRT	NR	23	not reached	adjuvant chemotherapy/hormonal therapy (80%)
Colorectal cancer
Kim et al. [55]	13	isolated lung metastases	retrospective observational	lung	SBRT	28	NR (PFS at 3 years: 11.5%)	NR (OS at 3 years: 64.7%)	chemotherapy (100%)
Takeda et al. [56]	15	lung oligometastases	retrospective observational with LC as primary endpoint	lung	SBRT	29	NA (LC at 2 years: 72%)a	NA	NA
Filippi et al. [57]	40	metachronous, at first lung progression	retrospective observational	lung	SBRT	20	8	46	pre-post SBRT chemotherapy (20%)
Qiu et al. [58]	65	synchronous/metachronous lung progression	retrospective observational	lung	SBRT	6.4	5.7	20.3	previous chemotherapy for metastatic disease (69%)
Comito et al. [59]	82	1–3 lung or liver metastases	retrospective observational	lung, liver	SBRT	24	14	32	pre-post SBRT chemotherapy (95%)

^aLocal control rates were compared with metastases from other origins and primary lung cancer, with statistically significant inferiority (P < 0.05). SRS = stereotactic radiosurgery, SBRT = stereotactic body radiation therapy, PFS = progression-free survival, OS = overall survival, LC = local control, NA = not applicable, NR = not reported.